Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A European Randomised Phase 3 Study to Assess the Efficacy and Safety of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance. Post Study 5-year Follow-up

NCT04017325 is registered in ClinicalTrials.gov with Steba Biotech S.A. as lead sponsor.

NCT NCT04017325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04017325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A European Randomised Phase 3 Study to Assess the Efficacy and Safety of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance. Post Study 5-year Follow-up
Lead sponsor
Steba Biotech S.A.
Phase
Observational
Overall status
Completed
Start date
March 17, 2016
Completion date
June 3, 2020
Enrollment
374 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of the prostate